- Home
- PFD vs PRQR Comparison
PFD vs PRQR Comparison
Compare PFD & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFD | PRQR |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 166.5M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PFD | PRQR |
|---|---|---|
| Price | $11.45 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 14.7K | ★ 696.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.86 | $1.33 |
| 52 Week High | $12.16 | $3.10 |
Technical Indicators
Market Signals| Indicator | PFD | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | 46.37 |
| Support Level | $10.98 | $1.36 |
| Resistance Level | $11.99 | $2.25 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 18.47 | 57.81 |
Price Performance
Historical ComparisonAbout PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.